Full-Time

Lead – Workday HCM

Deadline 7/31/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Compensation Overview

$84.3k - $102.2k/yr

+ Incentive Cash + Stock Opportunities

Company Historically Provides H1B Sponsorship

Tampa, FL, USA

Hybrid

Hybrid work model with at least 50% onsite at the assigned facility.

Category
💡Product (1)
Required Skills
Data Analysis
Requirements
  • Minimum education of a bachelor’s degree in IT, Business, or a related field is required.
  • Minimum of four (4) years of techno-functional experience in Workday HCM and reporting and analytics as a senior analyst, or product lead delivering and configuring solutions and full life-cycle implementations of HCM and reporting.
  • Strong problem-solving skills and ability to troubleshoot technical issues.
  • Excellent verbal and written communication, escalation, and conflict resolution skills.
  • Experience developing and delivering training programs.
  • Strong attention to detail and ability to maintain data accuracy and integrity.
  • A passion for excellent customer service, adaptable & flexible.
  • Ability to comply with handling sensitive and confidential employee data.
Responsibilities
  • Primary lead in the HCM module to include best practices for the system architecture from concept through requirements, design, build, test, deploy and maintain.
  • Provide subject matter expertise in any two modules of with excellent working knowledge on reporting and analytics best practices and partner with stakeholders to understand pain points, prioritize requirements, and identify opportunities to improve processes and gain efficiency by leveraging Workday functionality.
  • Identify business-critical Workday new features released (R1 & R2 releases) and demo to our stakeholders.
  • Understand the full HCM technology landscape, especially how third-party point solutions are utilized and integrated within Workday.
  • Develop partnerships with our HRIT organization business stakeholders and provide guidance on how to best leverage and utilize Workday for HCM and reporting.
  • Optimize, standardize, and automate the Workday HCM and reporting process across a global environment.
  • Assess current setup, configuration, systems, and utilization, and identify and recommend improvements.
  • Develop training to help end users with the adoption and usage of Workday.
  • Leverage your mastery-level knowledge of Workday reporting and analytics to lead the design, configuration, integration, data conversion, security, testing, reporting, postproduction support, and change management activities.
  • Collaborate closely with other Workday SMEs to leverage knowledge, other solutions, and best practices to ensure a holistic best-practice approach.
  • Review the Workday new product releases, identify features and functionality to adopt, and coordinate the planning and execution, and testing of those delivered features.
  • Accurately estimate effort and resources required to complete projects as related to areas of expertise.
  • Mentor and guide more junior colleagues for their roles in configuration and testing.
  • Utilize a case tool for capturing all inquiries, requests, and customer information.
Desired Qualifications
  • Workday Pro certified with mastery level experience in Workday HCM Core, Performance Management and reporting preferred.
  • Experience and knowledge of other Workday modules preferred (such as TA, Compensation, Benefits, Talent Management, etc.).

Bristol Myers Squibb (BMS) develops and delivers medicines for serious diseases, focusing on oncology, immunology, and cardiovascular conditions. The company invests heavily in research and development to create new drugs, which are sold to hospitals and patients after receiving regulatory approval. BMS also produces generic drugs, making healthcare more affordable while ensuring quality and safety. Committed to sustainability, BMS aims to improve patient outcomes and support the development of biosimilars.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Chris Shibutani's appointment may drive strategic growth and innovation at BMS.
  • Advancements in targeted protein degradation enhance therapeutic offerings in oncology.
  • Partnership with BioNTech could provide a competitive edge against Merck's Keytruda.

What critics are saying

  • Antitrust litigation over Pomalyst could impact BMS's market position in oncology.
  • Reliance on real-world data presents challenges in data quality and implementation.
  • High costs and technical challenges in space research could affect treatment feasibility.

What makes Bristol Myers Squibb unique

  • BMS collaborates with BioNTech for next-gen cancer immunotherapy, enhancing oncology portfolio.
  • Focus on real-world data strategies could lead to faster drug market entry.
  • Developing bone disease treatments in space positions BMS as a leader in innovative research.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

ISS National Lab
Jul 7th, 2025
This is Not the Time to Cut Space-enabled Medical Research

Bristol-Myers Squibb is developing novel bone disease treatments in space, and the National Stem Cell Foundation is studying 3D brain organoids derived from patients with Parkinson's disease in microgravity to observe disease progression more rapidly with the aim of identifying potential biomarkers for early diagnosis and therapeutic targets.

The Pharma Letter
Jun 26th, 2025
Bristol Myers faces new antitrust suit over multiple myeloma drug Pomalyst

Bristol Myers faces new antitrust suit over multiple myeloma drug Pomalyst.

Unlearn
Jun 24th, 2025
The Best 15 Minutes You'll Spend on Clinical Trials Today

At the 2025 "Digital Breakthrough for Pharma" Summit hosted by Bristol Myers Squibb, Unlearn's co-founder and machine learning scientist, Aaron Smith, took the stage to explain exactly how that vision is now a reality.

ROI-NJ
Jun 13th, 2025
Bristol Myers Squibb Names Shibutani As Evp, Chief Strategy Officer

Bristol Myers Squibb (BMS) this week appointed Chris Shibutani as executive vice president, chief strategy officer, effective immediately. Shibutani’s role is a new position on the BMS leadership team. The announcement was made on a LinkedIn post.Shibutani will lead the development and advancement of the company’s long-term strategic plan, collaborating across the enterprise to drive innovation and growth. He brings more than 25 years of experience in the financial services industry covering global pharmaceutical, biotechnology and medical device industries.Prior to BMS, Shibutani served as managing director in the global investment research division at Goldman Sachs. Previous roles include senior analyst positions at Hambrecht & Quist, Cowen, UBS, and J.P. Morgan.Before his career in finance, Shibutani was a physician trained in anesthesiology and critical care medicine at Massachusetts General Hospital and practiced at Memorial Sloan Kettering Cancer Center

PharmaData
Jun 13th, 2025
Bristol Myers Squibb Highlights Targeted Protein Degradation Data, Including CELMoD Agents, at EHA 2025

Bristol Myers Squibb highlights targeted protein degradation advances, including CELMoD agents and BCL6 Ligand-Directed Degrader, at EHA 2025 in Milan, Italy.